CL

Corline Biomedical ABFNSE Corline Biomedical Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Oct, 2024

Last price

Market cap $B

0.017

Micro

Exchange

FNSE - First North Sweden

CLBIO.ST Stock Analysis

CL

Uncovered

Corline Biomedical AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

17/100

Low score

Market cap $B

0.017

Dividend yield

Shares outstanding

21.491 B

Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-06-03. The company develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

View Section: Eyestock Rating